Ronipamil was developed as a verapamil analogue with a longer duration of action. However, it has much less calcium antagonist action than verapamil. Ronipamil has been tested for its ability to reduce ischaemia-induced arrhythmias in conscious rats. Compared to similar compounds, ronipamil was less effective and produced no statistically significant antiarrhythmic effects in rats. It had limited haemodynamic effects and no marked actions on blood pressure and heart rate. In another study, ronipamil prolonged survival time after traumatic shock and was shown to possess anti-shock potential. No information on current development of this drug is available.